BEIJING, Dec. 16, 2025 – PHIL RIVERS TECHNOLOGY Co., Ltd. today announced the successful closing of its Series A1 financing round.

The proceeds will be primarily used to advance its core drug pipeline, expand the global patent portfolio for its high-value intellectual property (IP), and enhance its computational medicine platform. These efforts aim to further unlock the potential of the company’s “Drug IP Innovation Factory” and spearhead the transformation of the R&D paradigm in the biopharmaceutical industry.